Divis Laboratories Ltd
Divis Laboratories Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Divi's Laboratories expects steady growth with constant currency growth at around 8.5% to 10% over the near term (Page 13). Divi's Laboratories aims for consistent double-digit growth, with an 8.5% constant currency growth achieved for 9 months ended December 2025.
From Divis Laboratories Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Divi's Laboratories expects steady growth with constant currency growth at around 8.5% to 10% over the near term (Page 13).
- Growth will be supported by a broad basket of custom synthesis (CS) products in various patent phases, balancing late life cycle, secondary source, and new product launches (Pages 9 and 13).
- Presence of multiple molecules in Phase II and Phase III clinical trials underpins a stable long-term growth trajectory (Page 13).
- Expansion of dedicated manufacturing blocks and peptide capacities is ongoing, with commercial scale readiness for new custom synthesis products expected post-2027 (Pages 12 and 17).
- Generics segment volume growth remains strong, though value growth is subdued due to pricing pressures; expectation of correction/improvement in generic API pricing is uncertain and depends on market dynamics (Pages 9 and 14).
- Nutraceutical business showed growth, contributing ₹706 crores in 9 months, indicating diversification (Page 6).
Profitability & Margins
See what Divis Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Divis Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is engaged in several custom synthesis projects, with 3 dedicated molecules currently validated and undergoing regulatory approvals.
- Validations for some products are completed, while others are ongoing or planned in the near term.
- Commercialization of these products is expected to start around the second half of FY '27, post regulatory approvals.
- Production blocks are mostly multipurpose, enabling quick scaling or adaptation for new products as needed.
- There is no specific quantitative order backlog shared due to confidentiality agreements with clients.
- Capacity expansions and backward integrations are ongoing to support anticipated demand.
- The company maintains a healthy volume growth and market share in generics and custom synthesis segments while continuously onboarding new molecules across various lifecycle stages.
Divis Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.8K Cr, net profit ₹751 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Divis Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
Frequently Asked Questions
What were Divis Laboratories Ltd Q3 FY26 results?
Divi's Laboratories expects steady growth with constant currency growth at around 8.5% to 10% over the near term (Page 13). Divi's Laboratories aims for consistent double-digit growth, with an 8.5% constant currency growth achieved for 9 months ended December 2025.
What is Divis Laboratories Ltd share price analysis?
Divis Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 75.5 with a market cap of ₹225,038 Cr. Investors should review the full earnings analysis for detailed insights.
Is Divis Laboratories Ltd planning capital expenditure?
Capex of ₹1,900 crores for FY '26 intimated to SEBI, slightly below initial guidance of ₹2,000 crores.
Keep Divis Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.